Charles River Laboratories International (NYSE:CRL) Given New $140.00 Price Target at Robert W. Baird

Charles River Laboratories International (NYSE:CRL - Free Report) had its price objective lifted by Robert W. Baird from $118.00 to $140.00 in a research report report published on Thursday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company's stock.

Other research analysts also recently issued research reports about the stock. William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. UBS Group reiterated a "neutral" rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Barclays dropped their price objective on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Finally, Mizuho decreased their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $176.00.

Charles River Laboratories International Stock Performance

Shares of CRL traded up $2.17 during mid-day trading on Thursday, reaching $145.25. 547,314 shares of the company's stock were exchanged, compared to its average volume of 970,592. The business's fifty day simple moving average is $137.91 and its 200-day simple moving average is $165.93. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market capitalization of $7.13 billion, a PE ratio of 968.33, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period in the previous year, the firm earned $2.27 EPS. The business's revenue was down 2.7% on a year-over-year basis. On average, equities research analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In related news, CEO James C. Foster purchased 6,075 shares of the stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. The trade was a 3.42% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction on Thursday, February 20th. The stock was bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Institutional Trading of Charles River Laboratories International

Several large investors have recently made changes to their positions in CRL. Veracity Capital LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at about $589,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Charles River Laboratories International by 46.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock worth $987,000 after buying an additional 1,679 shares in the last quarter. Boston Trust Walden Corp grew its holdings in shares of Charles River Laboratories International by 4.3% during the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock worth $37,748,000 after buying an additional 8,338 shares in the last quarter. Finally, E. Ohman J or Asset Management AB grew its holdings in shares of Charles River Laboratories International by 225.0% during the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock worth $480,000 after buying an additional 1,800 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).